Effectiveness of Bupropion Sustained Release for Smoking Cessation in a Health Care Setting: A Randomized Trial

Archives of Internal Medicine

Volumn 163, Issue 19, 2003, Pages 2337-2344

  Swan, Gary E ^a   McAfee, Tim ^b   Curry, Susan J ^b,c   Jack, Lisa M ^a   Javitz, Harold ^a   Dacey, Sara ^b   Bergman, Katherine ^b  

^a SRI INTERNATIONAL   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COUNSELING; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF REPORT; SMOKING CESSATION; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TREMOR;

ADULT; BUPROPION; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 0142150148     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.19.2337     Document Type: Article

References (26)

1. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
2. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bu propion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
3. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther. 2001;69:438-444.
4. Jamerson BD, Nides M, Jorenby DE, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther. 2001;23:744-752.
5. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571-1575.
6. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, Md: US Dept of Health and Human Services; 2000.
7. Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283:3244-3254.
8. Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry. 1998;59(suppl 4):66-72.
9. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. 1999;281:72-76.
10. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
11. Orleans CT, Schoenbach VJ, Wagner EH, et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. J Consult Clin Psychol. 1991;59:439-448.
12. McAfee T, Sofian NS, Wilson J, Hindmarsh M. The role of tobacco intervention in population-based health care: a case study. Am J Prev Med. 1998;14(suppl); 46-52.
13. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19: 1-15.
14. SAS Institute Inc. SAS/STAT User's Guide, Version 6. Vol 2. 4th ed. Cary, NC: SAS Institute Inc: 1989.
15. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712-720.
16. Glasgow RE, Mullooly JP, Vogt TM, et al. Biochemical validation of smoking status: pros, cons, and data from four low-intensity intervention trials. Addict Behav. 1993;18:511-527.
17. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health. 1991; 84:1086-1093.
18. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.
19. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21 (suppl):188S-194S.
20. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090; discussion, 1073.
21. Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull. 1992;111:23-41.
22. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol. 1995; 48:363-373.
23. Gilpin EA, Emory SL, Farkas AJ, Distefan JM, White MM, Pierce JP. The California Tobacco Control Program: A Decade of Progress: Results From the California Tobacco Survey, 1990-1999. La Jolla: University of California, San Diego; 2001.
24. Solberg LI, Boyle RG, Davidson G, Magnan S, Link Carlson C, Alesci NL. Aids to quitting tobacco use: how important are they outside controlled trials? Prev Med. 2001;33:53-58.
25. Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med. 2000;9:270-281.
26. Jack LM, Swan GE, Thompson E, et al. Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting. Prev Med. 2003;36:585-593.